2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1129

FCGR2A Polymorphism and Response to Anti-TNF Treatment in Rheumatoid Arthritis
Abstract Number: 2730

FcγRIIIa Ligation in Human Peripheral CD4⁺ T-Cells Generate T_H17 like Population
Abstract Number: 1176

Feasibility and Clinical Implication of Radiocarpal Cartilage T_1ρ MR Imaging in Rheumatoid Arthritis
Abstract Number: 1185

Feature of Fatty Deposition in Sacroiliac Joints in Ankylosing Spondylitis Patients Seen By MRI
Abstract Number: 2190

Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort
Abstract Number: 1312

Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
Abstract Number: 1197

Febuxostat Inhibits Monosodium Urate Crystal-Induced IL-1beta Secretion and Cell Death Via ROS- and Intracellular ATP-Dependent Pathways
Abstract Number: 578

Female Patients but Not Male Patients with Ankylosing Spondylitis Are at Increased Risk of Developing Ischemic Heart Disease: A Population-Based Cohort Study
Abstract Number: 1093

Female Sexual Function in Fibromyalgia
Abstract Number: 2736

Female Specific Increase in T Cell Glycosylation in Lupus
Abstract Number: 1011

Fibroblast Growth Factor-2 and Its Receptor Antagonists in Osteoarthritis
Abstract Number: 1022

Fibroblast-like Synovial Cells and Monocytes Team up in the Organization and the Dynamic Modelling of the Synovial Tissue
Abstract Number: 1001

Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Abstract Number: 1384

Fibromyalgia and Its Effect on Treatment Response in Early Rheumatoid Arthritis Patients
Abstract Number: 1117

Fibromyalgia Patients Taking Opioids Have Low Self-Efficacy and High Pain Catastrophizing but No Reduction in Pain or Improvement in Activity

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].